[Phase I study].
Criticisms and proposals were presented from the standpoint of implementation with regard to the objectives, person in charge, test facilities, patients tested and test design in the first phase cited in the "Guidelines For Methods To Evaluate Drugs for Malignant Tumors at the Clinical Level." Moreover, it was proposed that the public be informed as to the need and importance of scientific, theoretical and highly cost-efficient clinical trials.